Skip to main content
. 2018 May 25;97(21):e10350. doi: 10.1097/MD.0000000000010350

Figure 1.

Figure 1

Use of HER2-targeted adjuvant and neoadjuvant therapy in patients with HER2+ breast cancer. (A) Proportion of patients with HER2+ breast cancer receiving neoadjuvant therapy. The percentage value refers to the proportion of all patients (in each province) with HER2+ breast cancer that received neoadjuvant therapy. (B) Proportion of patients with HER2+ breast cancer receiving adjuvant therapy. The percentage value refers to the proportion of all patients (in each province) with HER2+ breast cancer who received adjuvant therapy.